PCSK9 inhibitors: a patent review 2018-2023

References

• Gu HM, Zhang DW. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9. J Biomed Res. 2015;29(5):356–361. doi: 10.7555/JBR.29.20150067
   PubMedGoogle Scholar
• Baigent C, Keech A, Kearney P, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2020;105(12):dgaa674. doi: 10.1210/clinem/dgaa674
   PubMed Web of Science ®Google Scholar
• Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–1066. doi: 10.1016/j.numecd.2014.05.009
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci. 2015;11(1):1–23. doi: 10.5114/aoms.2015.49807
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Ziajka PE. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Am J Cardiol. 2000;86(10):1123–1127. doi: 10.1016/S0002-9149(00)01171-1
   PubMed Web of Science ®Google Scholar
• Wong J, Quinn CM, Brown AJ. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. Biochem J. 2006;400(3):485–491. doi: 10.1042/BJ20060914
   PubMedGoogle Scholar
• Taylor BA, Thompson PD. Statins and their effect on PCSK9−impact and clinical relevance. Curr Atheroscler Rep. 2016;18(8):46. doi: 10.1007/s11883-016-0604-3
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470–486. doi: 10.1161/CIRCULATIONAHA.118.039107
   PubMed Web of Science ®Google Scholar
• Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs. 2010;13(2):103–111.
   PubMedGoogle Scholar
• Brandts J, Ray KK. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. Expert Opin Investig Drugs. 2020;29(8):763–770. doi: 10.1080/13543784.2020.1778668
   PubMed Web of Science ®Google Scholar
• Mourikis P, Zako S, Dannenberg L, et al. Lipid lowering therapy in cardiovascular disease: from myth to molecular reality. Pharmacol Ther. 2020;213:107592. doi: 10.1016/j.pharmthera.2020.107592
   PubMed Web of Science ®Google Scholar
• Shapiro MD, Tavori H, Fazio S. PCSK9 from basic science discoveries to clinical trials. Circ Res. 2018;122(10):1420–1438. doi: 10.1161/CIRCRESAHA.118.311227
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71–77. doi: 10.1016/j.tibs.2006.12.008
   PubMed Web of Science ®Google Scholar
• Peng J, Liu MM, Jin JL, et al. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):167. doi: 10.1186/s12933-020-01142-0
   PubMed Web of Science ®Google Scholar
• Seidah NG. The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob Cardiol Sci Pract. 2017;2017(1):e201702.
   PubMedGoogle Scholar
• Chaplin S. PCSK9 inhibitors: when statins aren’t enough. Prescriber. 2017;28(10):21–26. doi: 10.1002/psb.1616
   Google Scholar
• Tavori H, Melone M, Rashid SA. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014;12(10):1137–1144. doi: 10.1586/14779072.2014.954551
   PubMedGoogle Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34(1):1–9. doi: 10.1007/s40259-019-00399-6
   PubMed Web of Science ®Google Scholar
• Abifadel M, Pakradouni J, Collin M, et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat. 2010;20(11):1547–1571. doi: 10.1517/13543776.2010.518615
   PubMed Web of Science ®Google Scholar
• Elbitar S, El KP, Ghaleb Y, et al. Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opin Ther Pat. 2016;26(12):1377–1392. doi: 10.1080/13543776.2016.1206080
   PubMed Web of Science ®Google Scholar
• Cardio Therapeutics Pty Ltd. Heterocylic inhibitors of PCSK9. WO2018165718. 2018.
   Google Scholar
• Shifa Biomedical Corporation. Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases. WO2014150326. 2014.
   Google Scholar
• Evison BJ, Palmer JT, Lambert G, et al. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove. Bioorg Med Chem. 2020;28(6):115344. doi: 10.1016/j.bmc.2020.115344
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corporation. Substituted 1-methyl-tetrahydroisoquinoline molecules as PCSK9 allosteric binders. WO2018057409. 2018.
   Google Scholar
• Petrilli WL, Adam GC, Erdmann RS, et al. From screening to targeted degradation: strategies for the discovery and optimization of small molecule ligands for PCSK9. Cell Chem Biol. 2020;27(1):32–40.e3. doi: 10.1016/j.chembiol.2019.10.002
   PubMed Web of Science ®Google Scholar
• Gustafsen C, Olsen D, Vilstrup J, et al. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun. 2017;8(1):503. doi: 10.1038/s41467-017-00568-7
   PubMedGoogle Scholar
• Aarhus University. Compounds for treatment of lipoprotein metabolism disorders. WO2018054959. 2018.
   Google Scholar
• Coombe DR, Kett WC. Heparin mimetics. Handb Exp Pharmacol. 2012;207:361–383.
   Google Scholar
• Fennewald SM, Rando RF. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem. 1995;270(37):21718–21721. doi: 10.1074/jbc.270.37.21718
   PubMed Web of Science ®Google Scholar
• Guvakova MA, Yakubov LA, Vlodavsky I, et al. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem. 1995;270(6):2620–2627. doi: 10.1074/jbc.270.6.2620
   PubMed Web of Science ®Google Scholar
• China Pharmaceutical University. Application of kaempferol-3-O-rutinoside to preparation of medicine for treating PCSK9 (Proprotein convertase subtilisin/kexin type 9)-mediated disease. CN108567788. 2018.
   Google Scholar
• Li L, Fan ML, Li YN, et al. A rapid strategy for screening high-efficiency PCSK9 inhibitors from ginkgo biloba leaves by ligand fishing, HPLC-Q-TOF-MS and interdisciplinary assay. J Food Drug Anal. 2020;28(2):273–282. doi: 10.38212/2224-6614.1061
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corporation. PCSK9 antagonist compounds. JOP20190150. 2019.
   Google Scholar
• Merck Sharp & Dohme Corporation. PCSK9 antagonist bicyclo-compounds. WO2019246352. 2019.
   Google Scholar
• Novartis AG Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders. US2020164024. 2020.
   Google Scholar
• Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorder. WO2020110008. 2020.
   Google Scholar
• Brousseau ME, Clairmont KB, Spraggon G, et al. Identification of a PCSK9-LDLR disruptor peptide with in vivo function. Cell Chem Biol. 2022;29(2):249–258.e5. doi: 10.1016/j.chembiol.2021.08.012
   PubMed Web of Science ®Google Scholar
• Dogma Therapeutics Inc. PCSK9 inhibitors and methods of use thereof. WO2020150473. 2020.
   Google Scholar
• Pfizer. N-piperidin-3-ylbenziamide derivatives for treating cardiovascular diseases. WO2014170786. 2014.
   Google Scholar
• Tucker TJ, Embrey MW, Alleyne C, et al. A series of novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitors. J Med Chem. 2021;64(22):16770–16800. doi: 10.1021/acs.jmedchem.1c01599
   PubMed Web of Science ®Google Scholar
• Alleyne C, Amin RP, Bhatt B, et al. Series of novel and highly potent cyclic peptide PCSK9 inhibitors derived from an mRNA display screen and optimized via structure-based design. J Med Chem. 2020;63(22):13796–13824. doi: 10.1021/acs.jmedchem.0c01084
   PubMed Web of Science ®Google Scholar
• Iskandar SE, Bowers AA. mRNA display reaches for the clinic with new PCSK9 inhibitor. ACS Med Chem Lett. 2022;13(9):1379–1383. doi: 10.1021/acsmedchemlett.2c00319
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corporation. PCSK9 antagonist compounds. WO2021127460. 2021.
   Google Scholar
• Merck Sharp & Dohme Corporation. PCSK9 antagonist compounds. WO2021041770. 2021.
   Google Scholar
• Burnett JR, Hooper AJ. MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment. Expert Opin Investig Drugs. 2023;32(10):873–878.
   PubMed Web of Science ®Google Scholar
• Johns DG, Campeau LC, Banka P, et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023;148(2):144–158. doi: 10.1161/CIRCULATIONAHA.122.063372
   PubMed Web of Science ®Google Scholar
• Università degli studi di Milano. PCSK9-inhibiting compounds. WO2021234654. 2021.
   Google Scholar
• Stucchi M, Grazioso G, Lammi C, et al. Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic. Org Biomol Chem. 2016;14(41):9736–9740. doi: 10.1039/C6OB01642A
   PubMed Web of Science ®Google Scholar
• Lammi C, Sgrignani J, Roda G, et al. Inhibition of PCSK9D374Y/LDLR protein-protein interaction by computationally designed T9 lupin peptide. ACS Med Chem Lett. 2019;10(4):425–430. doi: 10.1021/acsmedchemlett.8b00464
   PubMed Web of Science ®Google Scholar
• Lammi C, Sgrignani J, Arnoldi A, et al. Biological characterization of computationally designed analogs of peptide TVFTSWEEYLDWV (Pep2-8) with increased PCSK9 antagonistic activity. Sci Rep. 2019;9(1):2343. doi: 10.1038/s41598-018-35819-0
   PubMedGoogle Scholar
• Lammi C, Zanoni C, Aiello G, et al. Lupin peptides modulate the protein-protein interaction of PCSK9 with the low density lipoprotein receptor in HepG2 cells. Sci Rep. 2016;6(1):29931. doi: 10.1038/srep29931
   PubMedGoogle Scholar
• Lammi C, Sgrignani J, Arnoldi A, et al. Computationally driven structure optimization, synthesis, and biological evaluation of imidazole-based proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors. J Med Chem. 2019;62(13):6163–6174. doi: 10.1021/acs.jmedchem.9b00402
   PubMed Web of Science ®Google Scholar
• McNutt MC, Kwon HJ, Chen C, et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem. 2009;284(16):10561–10570. doi: 10.1074/jbc.M808802200
   PubMed Web of Science ®Google Scholar
• Lammi C, Fassi EMA, Manenti M, et al. Computational design, synthesis, and biological evaluation of diimidazole analogues endowed with dual PCSK9/HMG-CoAR-inhibiting activity. J Med Chem. 2023;66(12):7943–7958. doi: 10.1021/acs.jmedchem.3c00279
   PubMed Web of Science ®Google Scholar
• Cardio Therapeutics Pty Ltd. Heterocyclic inhibitors of PCSK9. WO2022133529. 2022.
   Google Scholar
• Suchowerska AK, Stokman G, Palmer JT, et al. A novel, orally bioavailable, small-molecule inhibitor of PCSK9 with significant cholesterol-lowering properties in vivo. J Lipid Res. 2022;63(11):100293. doi: 10.1016/j.jlr.2022.100293
   PubMed Web of Science ®Google Scholar
• SRX Cardio LLC. Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9). US2022193058. 2022.
   Google Scholar
• Hebei Normal University & Institute of Medical Biotechnology CAMS. Benzothiazole compound as well as preparation method and application thereof. CN115109011. 2022.
   Google Scholar
• Daegu Gyeongbuk Medical Innovation Foundation & Kyungpook National University. Aminoalcohol derivative as PCSK9 inhibitor, and pharmaceutical composition for preventing or treating hypercholesterolemia, containing same. WO2022075645. 2022.
   Google Scholar
• Shengke Pharmaceuticals Jiangsu LTD. Novel compounds as inhibitors of PCSK9. WO2023280155. 2023.
   Google Scholar
• China Pharmaceutical University. Medical application of compounds with PCSK9 inhibitory activity. CN115770247. 2023.
   Google Scholar
• Yeang C, Karwatowska-Prokopczuk E, Su F, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035–1046. doi: 10.1016/j.jacc.2021.12.032
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Alexander VJ, Yang Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(5):264–275. doi: 10.1016/S2213-8587(21)00046-2
   PubMed Web of Science ®Google Scholar